Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Head and Neck Cancer—Diagnostics, Prevention and Management
share announcement

Head and Neck Cancer—Diagnostics, Prevention and Management

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Omics/Informatics".

Deadline for manuscript submissions: closed (20 June 2023) | Viewed by 3504

Special Issue Editor

Prof. Dr. Demeng Chen

E-Mail
Guest Editor
Center for Translational Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
Interests: key biochemical markers and the pathogenesis of head and neck cancer

Special Issue Information

Dear Colleagues,

Head and neck cancer is the seventh most common type of cancer worldwide and comprises a diverse group of tumors affecting the upper aerodigestive tract. In 2018, 890,000 new cases and 450,000 deaths were reported globally.

Although major advances have been made in the management of this disease and in determining the cause of its occurrence, improvement in the survival rate for HNSCC has been modest in the past three decades. Head and neck cancer remains a highly complex disease with a profound impact on patients and their quality of life.

We are pleased to invite you to submit basic research aimed at improving technologies for the prevention, diagnosis, risk assessment, and treatment of head and neck cancer.

This Special Issue aims to familiarize physicians and researchers with the latest advances in such research from the standpoint of diagnostics, prevention, and management.

We welcome original research articles and reviews, with research areas including (but not limited to):

  • Experimental research in the field of head and neck cancer;
  • Genomics, GWAS, and population genetics in head and neck cancer;
  • Head and neck cancer epigenetics;
  • Proteomic investigation of head and neck cancer;
  • Etiopathogenetic aspects of head and neck cancer;
  • Metabolic disorders of head and neck cancer;
  • Tumor microenvironment of head and neck cancer;
  • Individual management of head and neck cancer;
  • Lineage tracing and evolution of head and neck cancer.

We look forward to receiving your contributions.

Prof. Dr. Demeng Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • head and neck cancer
  • diagnostics and prevention
  • individual management
  • genomics and proteomics
  • tumor evolution
  • pathology
  • cancer stem cell
  • lineage tracing

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 4587 KiB  
Article
Immune Status of Cervical Lymph Nodes in Head and Neck Cancer—A Surgical Oncology Perspective
by Hiromu Nakamura, Tetsuya Ogawa, Shunpei Yamanaka, Daisuke Inukai, Takashi Maruo, Taishi Takahara, Akira Satou, Toyonori Tsuzuki, Susumu Suzuki, Ryuzo Ueda and Yasushi Fujimoto
J. Pers. Med. 2023, 13(7), 1174; https://doi.org/10.3390/jpm13071174 - 22 Jul 2023
Cited by 1 | Viewed by 1276
Abstract
Neck dissection for cervical lymph node metastasis is an established procedure for head and neck cancer (HNC). However, with the advent of immunotherapy, head and neck surgical oncologists need to rethink removing all lymph nodes, including those with immune function. We investigated the [...] Read more.
Neck dissection for cervical lymph node metastasis is an established procedure for head and neck cancer (HNC). However, with the advent of immunotherapy, head and neck surgical oncologists need to rethink removing all lymph nodes, including those with immune function. We investigated the anti-cancer immune response of the cervical lymph nodes in four patients with human papillomavirus type 16 (HPV16)-positive head and neck squamous cell carcinoma. Using lymphocytes extracted from local, metastatic, and non-metastatic lymph nodes and peripheral blood from these patients, we performed an intracellular flow cytometric cytokine assay using anti-IFNγ and anti-TNF-α monoclonal antibodies to detect HPV16 E6- and E7-specific T cells. HPV status and p16 immunostaining were determined by in situ detection using the HPV RNAscope method and immunohistochemistry. In one case, E6-specific and E7-specific CD8+ T cells were detected in proximal metastatic nodes and distal non-metastatic nodes. This finding suggests that non-metastatic nodes should be preserved for their immune function during neck dissection and that the immune function of non-metastatic lymph nodes is important when administering immunotherapy. In this context, head and neck surgical oncologists treating HNC should consider the place of immunotherapy and neck dissection in the treatment of HNC. Full article
(This article belongs to the Special Issue Head and Neck Cancer—Diagnostics, Prevention and Management)
►▼ Show Figures

Figure 1

10 pages, 261 KiB  
Article
A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer
by Dirk Rades, Inga Zwaan, Christian Idel, Ralph Pries, Karl L. Bruchhage, Samer G. Hakim, Nathan Y. Yu and Tamer Soror
J. Pers. Med. 2023, 13(7), 1120; https://doi.org/10.3390/jpm13071120 - 10 Jul 2023
Viewed by 802
Abstract
Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors and developed a prognostic instrument to help identify these patients. Ten pre-treatment characteristics were retrospectively analyzed in 154 [...] Read more.
Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors and developed a prognostic instrument to help identify these patients. Ten pre-treatment characteristics were retrospectively analyzed in 154 patients with head and neck cancer who were treated via chemoradiation with cisplatin. These pre-treatment characteristics included age, sex, Karnofsky performance score, tumor site, primary tumor stage, nodal stage, histologic grade, upfront surgery, human papilloma virus status, and history of smoking. The characteristics significantly associated with the completion of cisplatin-based treatment, the receipt of ≥80% cisplatin, or showing a strong trend of association after multivariate analyses were used for the prognostic instrument. For each characteristic, 0 points were assigned for worse outcomes, and 1 point was assigned for better outcomes. Patients’ scores were calculated by adding these points. Age ≤ 60 years and a Karnofsky performance score of 90–100 were significantly associated with both endpoints after multivariate analysis, and male gender showed a trend for association with the receipt of ≥80% cisplatin. Patient scores were 0, 1, 2, and 3 points. The corresponding rates of completion of cisplatin-based treatment were 14%, 41%, 62%, and 72%, respectively (p = 0.004). The rates of receipt of ≥80% cisplatin were 29%, 54%, 72%, and 94%, respectively (p < 0.001). This new prognostic instrument helps to predict whether head and neck cancer patients scheduled for chemoradiation will receive cisplatin as planned. Full article
(This article belongs to the Special Issue Head and Neck Cancer—Diagnostics, Prevention and Management)
13 pages, 878 KiB  
Article
First Results of Concurrent Chemoradiation with Two Courses of 5 × 25 mg/m2 Cisplatin for Locally Advanced Head and Neck Cancer
by Inga Zwaan, Tamer Soror, Christian Idel, Ralph Pries, Karl L. Bruchhage, Samer G. Hakim, Nathan Y. Yu and Dirk Rades
J. Pers. Med. 2023, 13(6), 1006; https://doi.org/10.3390/jpm13061006 - 16 Jun 2023
Viewed by 1022
Abstract
Many patients with squamous cell carcinoma of the head and neck (SCCHN) receive cisplatin-based chemoradiation. Cisplatin 100 mg/m2 every three weeks is toxic and alternative cisplatin regimens are desired. Two courses of 20 mg/m2/day 1–5 (cumulative 200 mg/m2) [...] Read more.
Many patients with squamous cell carcinoma of the head and neck (SCCHN) receive cisplatin-based chemoradiation. Cisplatin 100 mg/m2 every three weeks is toxic and alternative cisplatin regimens are desired. Two courses of 20 mg/m2/day 1–5 (cumulative 200 mg/m2) were shown to be similarly effective and better tolerated than 100 mg/m2 every three weeks. Previous studies suggested that cumulative doses >200 mg/m2 may further improve outcomes. In this study, 10 patients (group A) receiving two courses of 25 mg/m2/day 1–5 (cumulative 250 mg/m2) in 2022 were retrospectively matched and compared to 98 patients (group B) receiving two courses of 20 mg/m2/day 1–5 or 25 mg/m2/day 1–4 (cumulative 200 mg/m2). Follow-up was limited to 12 months to avoid bias. Group A achieved non-significantly better 12-month loco-regional control (100% vs. 83%, p = 0.27) and metastases-free survival (100% vs. 88%, p = 0.38), and similar overall survival (89% vs. 88%, p = 0.90). No significant differences were found regarding toxicities, completion of chemotherapy, and interruption of radiotherapy. Given the limitations of this study, chemoradiation with two courses of 25 mg/m2/day 1–5 appears an option for carefully selected patients as a personalized treatment approach. Longer follow-up and a larger sample size are needed to properly define its role. Full article
(This article belongs to the Special Issue Head and Neck Cancer—Diagnostics, Prevention and Management)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop